We are live on ! Find out more
NAGE

Niagen Bioscience
NAGE

61 hedge funds and large institutions have $32.7M invested in Niagen Bioscience in 2018 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 14

0.01% less ownership

Funds ownership: 17.33% → 17.32% (-0.01%)

5% less funds holding

Funds holding: 64 → 61 (-3)

20% less capital invested

Capital invested by funds: $40.9M → $32.7M (-$8.12M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
61
Holders Change
-3
Holders Change %
-4.69%
% of All Funds
1.36%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
16
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of New York Mellon
Bank of New York Mellon
New York
+$84.8K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$78K
3
BFM
Boothbay Fund Management
New York
+$60.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$60.3K
5
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$58.6K

Top Sellers

Rank Fund Capital Flow
1
OC
Oppenheimer & Co
New York
-$148K
2
Deutsche Bank
Deutsche Bank
Germany
-$128K
3
ARTA
A.R.T. Advisors
New York
-$93K
4
Jane Street
Jane Street
New York
-$90K
5
WSTAM
Wilbanks Smith & Thomas Asset Management
Virginia
-$86K
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
51
Horan Securities
United States
$8K – – –
CPA
52
Cowen Prime Advisors
New York
$8K +$7.64K +2,200 New
RE
53
RBC Europe
United Kingdom
$2.64K – – –
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$2K -$2.42K -695 -59%
AA
55
AlphaMark Advisors
Kentucky
$2K – – –
VFA
56
Valeo Financial Advisors
Indiana
$2K – – –
Bank of Montreal
57
Bank of Montreal
Ontario, Canada
$2K +$966 +278 +105%
Barclays
58
Barclays
United Kingdom
$1K -$50.6K -14,560 -97%
BOPW
59
Brandywine Oak Private Wealth
Pennsylvania
$1K +$1.04K +300 New
CG
60
Cutler Group
California
$1K +$1.74K +500 New
ARTA
61
A.R.T. Advisors
New York
– -$93K -21,771 Closed
Jane Street
62
Jane Street
New York
– -$90K -21,058 Closed
WSTAM
63
Wilbanks Smith & Thomas Asset Management
Virginia
– -$86K -20,000 Closed
Ameriprise
64
Ameriprise
Minnesota
– -$64K -14,827 Closed
GCP
65
GSA Capital Partners
United Kingdom
– -$59K -13,700 Closed
DWM
66
Dynasty Wealth Management
Florida
– -$44K -10,300 Closed
William Blair & Company
67
William Blair & Company
Illinois
– -$43K -10,000 Closed
OGC
68
Oak Grove Capital
New Hampshire
– -$21K -5,000 Closed
Simplex Trading
69
Simplex Trading
Illinois
– -$14K -3,264 Closed
BNP Paribas Financial Markets
70
BNP Paribas Financial Markets
France
– -$5.4K -1,258 Closed
Carson Wealth (CWM LLC)
71
Carson Wealth (CWM LLC)
Nebraska
– +$69 +20 New
1 2
3

NAGE Hedge Fund Activity: Q4 2018 in Review

61 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q4 2018, worth a combined $32.7M — down 20% from $40.9M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NAGE and 7 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 16 added.

The largest buyer was Bank of New York Mellon, adding an estimated $84.8K. The largest seller was Oppenheimer & Co, cutting an estimated $148K.

  • 61 institutional investors held Niagen Bioscience (NAGE) as of Q4 2018, down from 64 in Q3 2018.
  • Funds reported $32.7M of Niagen Bioscience stock for Q4 2018, down 20% quarter-over-quarter.
  • 7 funds opened new Niagen Bioscience positions in Q4 2018 and 10 closed out, a net change of -3 holders.
  • The largest Niagen Bioscience buyer in Q4 2018 was Bank of New York Mellon, an estimated $84.8K added.
  • The largest Niagen Bioscience seller in Q4 2018 was Oppenheimer & Co, an estimated $148K sold.

Based on aggregated 13F filings for Q4 2018.